Enhanced conversion of T cells into CAR T cells by modulation of the MAPK/ERK pathway
Delivery of chimeric antigen receptors (CARs) to T cells is usually mediated by lentiviral vectors (LVs), which can have broad tropism or be T cell targeted. To better understand the molecular events during CAR T cell generation, T cell transduction with four different LVs is followed by single-cell multi-omics analysis, distinguishing between transduced T cells and T cells with vector signal but no CAR. We find that only a fraction of the T cells that encounter vectors convert into CAR T cells. Single-cell transcriptome data reveal that interferon-stimulated genes are upregulated in non-transduced cells, whereas extracellular signal-regulated kinase (ERK)2 phosphatases are upregulated in CAR T cells. This expression pattern is evident in CAR T cells from healthy donors and patients. The role of the mitogen-activated protein kinase (MAPK)/ERK pathway in CAR T cell generation is confirmed by chemical inhibitors. These data provide molecular insights into T cell transduction with implications for improving CAR T cell generation.
Authors
- Frederic B. Thalheimer (ORCID: https://orcid.org/0000-0003-0423-099X)
- Filippos T. Charitidis (ORCID: https://orcid.org/0000-0002-4802-1391)
- Colin Clarke (ORCID: https://orcid.org/0000-0003-2817-9527)
- Christian J. Buchholz (ORCID: https://orcid.org/0000-0002-9837-7345)
- Elham Adabi (ORCID: https://orcid.org/0000-0003-2009-4633)
- Mar Guaza-Lasheras
Institutions
- University College Dublin (IE)
- Goethe University Frankfurt (DE)
- German Cancer Research Center (DE)
- National Institute for Bioprocessing Research and Training (IE)
- Frankfurt Cancer Institute (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Paul Ehrlich Institut (DE)
Publication Details
- Journal
- Cell Reports Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.xcrm.2025.101970
- Citations
- 4
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- Innovative Medicines Initiative
- H2020 Marie Skłodowska-Curie Actions